The Code of best Practice of reporting by Life Science Companies...

The Code of best Practice of reporting by Life Science Companies recognises the importance of peer review in the validation process and acknowledges that in some circumstances disclosure of results before peer review may be premature.

Be very interesting to know if results are being peer reviewed before release to the market Per the prior peer reviewed abstract (SARS-CoV-2) "BIT225 showed broad-spectrum direct-acting antiviral activity against SARS-CoV-2 in Calu3 and Vero cells with similar potency across 6 different virus strains."

Such ground-breaking validation in humans would make BIT225 a compelling new-generation small molecule direct-acting antiviral agent with fewer drug-drug-interactions, fewer safety and tolerability concerns, and broad-spectrum antiviral activity. BP are on the hunt for options with different mechanisms of action to prepare for the emergence of transmissible drug-resistant variants to the first-generation molecules when treating SARS-CoV-2.... Also lets not forget BIT225 potential to reduce HIV-1 replication, HIV-1 reservoirs and inflammation associated with chronic HIV-1 infection.